Oritavancin Diphosphate is Used for treating acute bacterial skin and skin structure infections with a single dose of 1200mg of oritavancin or its equivalent. It was first introduced by Melinta Therapeutics Llc in its drug Orbactiv on Aug 6, 2014. Another drug containing Oritavancin Diphosphate is Kimyrsa.

Oritavancin Diphosphate Patents

Given below is the list of patents protecting Oritavancin Diphosphate, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Kimyrsa	US9649352	High purity oritavancin and method of producing same	Jul 16, 2035	Melinta Therap
Orbactiv	US9649352	High purity oritavancin and method of producing same	Jul 16, 2035	Melinta Therap
Kimyrsa	US9682061	Methods of treating bacterial infections using oritavancin	Apr 26, 2030	Melinta Therap
Orbactiv	US9682061	Methods of treating bacterial infections using oritavancin	Apr 26, 2030	Melinta Therap
Kimyrsa	US8420592	Methods of treatment using single doses of oritavancin	Aug 29, 2029	Melinta Therap
Orbactiv	US8420592	Methods of treatment using single doses of oritavancin	Aug 29, 2029	Melinta Therap
Orbactiv	US5840684	Glycopeptide antibiotic derivatives	Nov 24, 2020 (Expired)	Melinta Therap
Orbactiv	US5998581	Reductive alkylation of glycopeptide antibiotics	Nov 12, 2017 (Expired)	Melinta Therap

Add above patents to watchlist

Oritavancin Diphosphate's Family Patents

Full family tree